ABSTRACT
Better biomarkers to predict death early in acute liver failure (ALF) are needed. To that end, we obtained early (study day 1) and later (day 3) serum samples from transplant-free survivors (n=28) and non-survivors (n=30) of acetaminophen (APAP)-induced ALF from the NIH-sponsored Acute Liver Failure Study Group, and from control volunteers (n=10). To identify proteins that increase early in serum during ALF, we selected individuals from this cohort for whom ALT was lower on day 1 than day 3, indicating a time point before the peak of injury (n=10/group). We then performed untargeted proteomics on their day 1 samples. Out of 1,682 quantifiable proteins, 79 were elevated ≥4-fold in ALF patients vs. controls and 23 of those were further elevated ≥4-fold in non-survivors vs. survivors, indicating potential to predict death. Interestingly, the biomarker with best performance was LDH. To confirm the prognostic potential of LDH, we measured activity in all day 1 and 3 samples from all 58 ALF patients. LDH was elevated in the non-survivors vs. survivors on both days. In addition, receiver operating characteristic (ROC) curve analyses revealed that LDH alone performed similarly to the model for end-stage liver disease (MELD), while a combination of MELD and LDH outperformed either alone. Finally, Upstream Analysis of our proteomics data indicated activation of LKB1-AMPK signaling in liver regeneration after APAP overdose and we confirmed that in mice. Overall, we conclude LDH can predict death in APAP-induced ALF and that LKB1-AMPK signaling may be a promising therapeutic target to improve survival.
Competing Interest Statement
MRM has consulted for Acetaminophen Toxicity Diagnostics, LLC; Alkermes Pharmaceuticals; and GlaxoSmithKline.
Funding Statement
The ALFSG is funded by National Institutes of Health (NIH) grant U01DK058369 (to WML). The IDeA National Resource for Quantitative Proteomics at UAMS is supported in part by NIH grant R24GM137786. Additional funding was provided by a 2018 Pinnacle Research Award from the AASLD Foundation (to MRM) and NIH grants R01DK102142 (to HJ) and T32GM106999 (to JHV; PI: Dr. Paul Prather).
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
IRB of the University of Arkansas for Medical Sciences gave ethical approval for this work. IRB of Albert Einstein Medical Center gave ethical approval for this work. IRB of Baylor University Medical Center gave ethical approval for this work. IRB of Emory University gave ethical approval for this work. IRB of Massachusetts General Hospital gave ethical approval for this work. IRB of Mayo Clinic gave ethical approval for this work. IRB of Medical University of South Carolina gave ethical approval for this work. IRB of Mount Sinai School of Medicine gave ethical approval for this work. IRB of Northwestern University Feinberg School of Medicine gave ethical approval for this work. IRB of The Ohio State University gave ethical approval for this work. IRB of Oregon Health Sciences University gave ethical approval for this work. IRB of University of Alabama at Birmingham gave ethical approval for this work. IRB of University of Alberta gave ethical approval for this work. IRB of University of California at San Francisco gave ethical approval for this work. IRB of University of Kansas Medical Center gave ethical approval for this work. IRB of University of Michigan Medical Center gave ethical approval for this work. IRB of University of Nebraska Medical Center gave ethical approval for this work. IRB of University of Pennsylvania gave ethical approval for this work. IRB of University of Pittsburgh Medical Center gave ethical approval for this work. IRB of University of Texas Southwestern Medical Center gave ethical approval for this work. IRB of University of Washington gave ethical approval for this work. IRB of Virginia Commonwealth University gave ethical approval for this work. IRB of Yale University gave ethical approval for this work.
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Data Availability
All data produced in the present study are available upon reasonable request by academic researchers to the authors.
